Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 678

1.

Cryo-EM structure of the Ebola virus nucleoprotein-RNA complex at 3.6 Å resolution.

Sugita Y, Matsunami H, Kawaoka Y, Noda T, Wolf M.

Nature. 2018 Oct 17. doi: 10.1038/s41586-018-0630-0. [Epub ahead of print]

PMID:
30333622
2.

Recurring and Adaptable Binding Motifs in Broadly Neutralizing Antibodies to Influenza Virus Are Encoded on the D3-9 Segment of the Ig Gene.

Wu NC, Yamayoshi S, Ito M, Uraki R, Kawaoka Y, Wilson IA.

Cell Host Microbe. 2018 Oct 10;24(4):569-578.e4. doi: 10.1016/j.chom.2018.09.010.

PMID:
30308159
3.

Differences in the ease with which mutant viruses escape from human monoclonal antibodies against the HA stem of influenza A virus.

Yamayoshi S, Yasuhara A, Ito M, Uraki R, Kawaoka Y.

J Clin Virol. 2018 Sep 26;108:105-111. doi: 10.1016/j.jcv.2018.09.016. [Epub ahead of print]

PMID:
30292135
4.

The Cellular DExD/H-Box RNA Helicase UAP56 Co-localizes With the Influenza A Virus NS1 Protein.

Chiba S, Hill-Batorski L, Neumann G, Kawaoka Y.

Front Microbiol. 2018 Sep 12;9:2192. doi: 10.3389/fmicb.2018.02192. eCollection 2018.

5.

Effectiveness of Whole, Inactivated, Low Pathogenicity Influenza A(H7N9) Vaccine against Antigenically Distinct, Highly Pathogenic H7N9 Virus.

Hatta M, Zhong G, Chiba S, Lopes TJS, Neumann G, Kawaoka Y.

Emerg Infect Dis. 2018 Oct;24(10):1910-1913. doi: 10.3201/eid2410.180403.

6.

Selection of Antigenically Advanced Variants of Influenza Viruses.

Neumann G, Fan S, Kawaoka Y.

Methods Mol Biol. 2018;1836:461-486. doi: 10.1007/978-1-4939-8678-1_22.

PMID:
30151587
7.

Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection.

Saphire EO, Schendel SL, Fusco ML, Gangavarapu K, Gunn BM, Wec AZ, Halfmann PJ, Brannan JM, Herbert AS, Qiu X, Wagh K, He S, Giorgi EE, Theiler J, Pommert KBJ, Krause TB, Turner HL, Murin CD, Pallesen J, Davidson E, Ahmed R, Aman MJ, Bukreyev A, Burton DR, Crowe JE Jr, Davis CW, Georgiou G, Krammer F, Kyratsous CA, Lai JR, Nykiforuk C, Pauly MH, Rijal P, Takada A, Townsend AR, Volchkov V, Walker LM, Wang CI, Zeitlin L, Doranz BJ, Ward AB, Korber B, Kobinger GP, Andersen KG, Kawaoka Y, Alter G, Chandran K, Dye JM; Viral Hemorrhagic Fever Immunotherapeutic Consortium.

Cell. 2018 Aug 9;174(4):938-952.e13. doi: 10.1016/j.cell.2018.07.033.

8.

A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus.

Gunn BM, Yu WH, Karim MM, Brannan JM, Herbert AS, Wec AZ, Halfmann PJ, Fusco ML, Schendel SL, Gangavarapu K, Krause T, Qiu X, He S, Das J, Suscovich TJ, Lai J, Chandran K, Zeitlin L, Crowe JE Jr, Lauffenburger D, Kawaoka Y, Kobinger GP, Andersen KG, Dye JM, Saphire EO, Alter G.

Cell Host Microbe. 2018 Aug 8;24(2):221-233.e5. doi: 10.1016/j.chom.2018.07.009.

PMID:
30092199
9.

Host Factor Nucleoporin 93 Is Involved in the Nuclear Export of Influenza Virus RNA.

Furusawa Y, Yamada S, Kawaoka Y.

Front Microbiol. 2018 Jul 24;9:1675. doi: 10.3389/fmicb.2018.01675. eCollection 2018.

10.

The Induction of IL-1β Secretion Through the NLRP3 Inflammasome During Ebola Virus Infection.

Halfmann P, Hill-Batorski L, Kawaoka Y.

J Infect Dis. 2018 Jul 27. doi: 10.1093/infdis/jiy433. [Epub ahead of print]

PMID:
30060221
11.

N-Terminal Acetylation by NatB Is Required for the Shutoff Activity of Influenza A Virus PA-X.

Oishi K, Yamayoshi S, Kozuka-Hata H, Oyama M, Kawaoka Y.

Cell Rep. 2018 Jul 24;24(4):851-860. doi: 10.1016/j.celrep.2018.06.078.

12.

Strain-Specific Contribution of Eukaryotic Elongation Factor 1 Gamma to the Translation of Influenza A Virus Proteins.

Sammaibashi S, Yamayoshi S, Kawaoka Y.

Front Microbiol. 2018 Jun 29;9:1446. doi: 10.3389/fmicb.2018.01446. eCollection 2018.

13.

Novel influenza vaccine M2SR protects against drifted H1N1 and H3N2 influenza virus challenge in ferrets with pre-existing immunity.

Hatta Y, Boltz D, Sarawar S, Kawaoka Y, Neumann G, Bilsel P.

Vaccine. 2018 Aug 9;36(33):5097-5103. doi: 10.1016/j.vaccine.2018.06.053. Epub 2018 Jul 13.

14.

Development of an Influenza Rapid Diagnostic Kit Specific for the H7 Subtype.

Iwatsuki-Horimoto K, Shi J, Wang X, Sakai-Tagawa Y, Ito M, Murakami K, da Silva Lopes TJ, Nakaishi K, Yamayoshi S, Watabe S, Chen H, Kawaoka Y.

Front Microbiol. 2018 Jun 25;9:1346. doi: 10.3389/fmicb.2018.01346. eCollection 2018.

15.

In vivo imaging of the pathophysiological changes and neutrophil dynamics in influenza virus-infected mouse lungs.

Ueki H, Wang IH, Fukuyama S, Katsura H, da Silva Lopes TJ, Neumann G, Kawaoka Y.

Proc Natl Acad Sci U S A. 2018 Jul 10;115(28):E6622-E6629. doi: 10.1073/pnas.1806265115. Epub 2018 Jun 25.

PMID:
29941581
16.

Diversity of Influenza A(H5N1) Viruses in Infected Humans, Northern Vietnam, 2004-2010.

Imai H, Dinis JM, Zhong G, Moncla LH, Lopes TJS, McBride R, Thompson AJ, Peng W, Le MTQ, Hanson A, Lauck M, Sakai-Tagawa Y, Yamada S, Eggenberger J, O'Connor DH, Suzuki Y, Hatta M, Paulson JC, Neumann G, Friedrich TC, Kawaoka Y.

Emerg Infect Dis. 2018 Jul;24(7):1128-1238. doi: 10.3201/eid2407.171441.

17.

The Marmoset as an Animal Model of Influenza: Infection With A(H1N1)pdm09 and Highly Pathogenic A(H5N1) Viruses via the Conventional or Tracheal Spray Route.

Iwatsuki-Horimoto K, Nakajima N, Kiso M, Takahashi K, Ito M, Inoue T, Horiuchi M, Okahara N, Sasaki E, Hasegawa H, Kawaoka Y.

Front Microbiol. 2018 May 9;9:844. doi: 10.3389/fmicb.2018.00844. eCollection 2018.

18.

Isolation of an Egg-Adapted Influenza A(H3N2) Virus without Amino Acid Substitutions at the Antigenic Sites of Its Hemagglutinin.

Kuwahara T, Takashita E, Fujisaki S, Shirakura M, Nakamura K, Kishida N, Takahashi H, Suzuki N, Kawaoka Y, Watanabe S, Odagiri T.

Jpn J Infect Dis. 2018 May 24;71(3):234-238. doi: 10.7883/yoken.JJID.2017.551. Epub 2018 Apr 27.

19.

Evaluation of the fusion partner cell line SPYMEG for obtaining human monoclonal antibodies against influenza B virus.

Soni P, Yasuhara A, Takenaga T, Iwatsuki-Horimoto K, Uraki R, Ito M, Sasaki T, Ikuta K, Yamayoshi S, Kawaoka Y.

J Vet Med Sci. 2018 Jun 29;80(6):1020-1024. doi: 10.1292/jvms.18-0146. Epub 2018 Apr 17.

20.

A Critical Domain of Ebolavirus Envelope Glycoprotein Determines Glycoform and Infectivity.

Fujihira H, Usami K, Matsuno K, Takeuchi H, Denda-Nagai K, Furukawa JI, Shinohara Y, Takada A, Kawaoka Y, Irimura T.

Sci Rep. 2018 Apr 3;8(1):5495. doi: 10.1038/s41598-018-23357-8.

21.

Experimental infection of Cynomolgus Macaques with highly pathogenic H5N1 influenza virus through the aerosol route.

Watanabe T, Iwatsuki-Horimoto K, Kiso M, Nakajima N, Takahashi K, Jose da Silva Lopes T, Ito M, Fukuyama S, Hasegawa H, Kawaoka Y.

Sci Rep. 2018 Mar 19;8(1):4801. doi: 10.1038/s41598-018-23022-0.

22.

Influenza A virus nucleoprotein is acetylated by histone acetyltransferases PCAF and GCN5.

Hatakeyama D, Shoji M, Yamayoshi S, Yoh R, Ohmi N, Takenaka S, Saitoh A, Arakaki Y, Masuda A, Komatsu T, Nagano R, Nakano M, Noda T, Kawaoka Y, Kuzuhara T.

J Biol Chem. 2018 May 11;293(19):7126-7138. doi: 10.1074/jbc.RA117.001683. Epub 2018 Mar 19.

23.

Enhanced Replication of Highly Pathogenic Influenza A(H7N9) Virus in Humans.

Yamayoshi S, Kiso M, Yasuhara A, Ito M, Shu Y, Kawaoka Y.

Emerg Infect Dis. 2018 Apr;24(4):746-750. doi: 10.3201/eid2404.171509.

24.

Stimulation of alpha2-adrenergic receptors impairs influenza virus infection.

Matsui K, Ozawa M, Kiso M, Yamashita M, Maekawa T, Kubota M, Sugano S, Kawaoka Y.

Sci Rep. 2018 Mar 15;8(1):4631. doi: 10.1038/s41598-018-22927-0.

25.

Lung-Derived Exosomal miR-483-3p Regulates the Innate Immune Response to Influenza Virus Infection.

Maemura T, Fukuyama S, Sugita Y, Lopes TJS, Nakao T, Noda T, Kawaoka Y.

J Infect Dis. 2018 Apr 11;217(9):1372-1382. doi: 10.1093/infdis/jiy035.

PMID:
29373693
26.

MERS-CoV and H5N1 influenza virus antagonize antigen presentation by altering the epigenetic landscape.

Menachery VD, Schäfer A, Burnum-Johnson KE, Mitchell HD, Eisfeld AJ, Walters KB, Nicora CD, Purvine SO, Casey CP, Monroe ME, Weitz KK, Stratton KG, Webb-Robertson BM, Gralinski LE, Metz TO, Smith RD, Waters KM, Sims AC, Kawaoka Y, Baric RS.

Proc Natl Acad Sci U S A. 2018 Jan 30;115(5):E1012-E1021. doi: 10.1073/pnas.1706928115. Epub 2018 Jan 16.

27.

Ebola virus requires a host scramblase for externalization of phosphatidylserine on the surface of viral particles.

Nanbo A, Maruyama J, Imai M, Ujie M, Fujioka Y, Nishide S, Takada A, Ohba Y, Kawaoka Y.

PLoS Pathog. 2018 Jan 16;14(1):e1006848. doi: 10.1371/journal.ppat.1006848. eCollection 2018 Jan.

28.

Identification of novel amino acid residues of influenza virus PA-X that are important for PA-X shutoff activity by using yeast.

Oishi K, Yamayoshi S, Kawaoka Y.

Virology. 2018 Mar;516:71-75. doi: 10.1016/j.virol.2018.01.004. Epub 2018 Jan 10.

PMID:
29331676
29.

Influenza C and D Viruses Package Eight Organized Ribonucleoprotein Complexes.

Nakatsu S, Murakami S, Shindo K, Horimoto T, Sagara H, Noda T, Kawaoka Y.

J Virol. 2018 Feb 26;92(6). pii: e02084-17. doi: 10.1128/JVI.02084-17. Print 2018 Mar 15.

30.

Importance of the 1+7 configuration of ribonucleoprotein complexes for influenza A virus genome packaging.

Noda T, Murakami S, Nakatsu S, Imai H, Muramoto Y, Shindo K, Sagara H, Kawaoka Y.

Nat Commun. 2018 Jan 4;9(1):54. doi: 10.1038/s41467-017-02517-w.

31.

Characterization of a Feline Influenza A(H7N2) Virus.

Hatta M, Zhong G, Gao Y, Nakajima N, Fan S, Chiba S, Deering KM, Ito M, Imai M, Kiso M, Nakatsu S, Lopes TJ, Thompson AJ, McBride R, Suarez DL, Macken CA, Sugita S, Neumann G, Hasegawa H, Paulson JC, Toohey-Kurth KL, Kawaoka Y.

Emerg Infect Dis. 2018 Jan;24(1):75-86. doi: 10.3201/eid2401.171240.

32.

Diversity of antigenic mutants of influenza A(H1N1)pdm09 virus escaped from human monoclonal antibodies.

Yasuhara A, Yamayoshi S, Soni P, Takenaga T, Kawakami C, Takashita E, Sakai-Tagawa Y, Uraki R, Ito M, Iwatsuki-Horimoto K, Sasaki T, Ikuta K, Yamada S, Kawaoka Y.

Sci Rep. 2017 Dec 18;7(1):17735. doi: 10.1038/s41598-017-17986-8.

33.

Human protective monoclonal antibodies against the HA stem of group 2 HAs derived from an H3N2 virus-infected human.

Yamayoshi S, Ito M, Uraki R, Sasaki T, Ikuta K, Kawaoka Y.

J Infect. 2018 Feb;76(2):177-185. doi: 10.1016/j.jinf.2017.12.004. Epub 2017 Dec 14.

PMID:
29248585
34.

Mutations in the PA Protein of Avian H5N1 Influenza Viruses Affect Polymerase Activity and Mouse Virulence.

Zhong G, Le MQ, Lopes TJS, Halfmann P, Hatta M, Fan S, Neumann G, Kawaoka Y.

J Virol. 2018 Jan 30;92(4). pii: e01557-17. doi: 10.1128/JVI.01557-17. Print 2018 Feb 15.

35.

Syrian Hamster as an Animal Model for the Study of Human Influenza Virus Infection.

Iwatsuki-Horimoto K, Nakajima N, Ichiko Y, Sakai-Tagawa Y, Noda T, Hasegawa H, Kawaoka Y.

J Virol. 2018 Jan 30;92(4). pii: e01693-17. doi: 10.1128/JVI.01693-17. Print 2018 Feb 15.

36.

Combination Therapy With Neuraminidase and Polymerase Inhibitors in Nude Mice Infected With Influenza Virus.

Kiso M, Lopes TJS, Yamayoshi S, Ito M, Yamashita M, Nakajima N, Hasegawa H, Neumann G, Kawaoka Y.

J Infect Dis. 2018 Mar 5;217(6):887-896. doi: 10.1093/infdis/jix606.

PMID:
29186472
37.

Multi-platform 'Omics Analysis of Human Ebola Virus Disease Pathogenesis.

Eisfeld AJ, Halfmann PJ, Wendler JP, Kyle JE, Burnum-Johnson KE, Peralta Z, Maemura T, Walters KB, Watanabe T, Fukuyama S, Yamashita M, Jacobs JM, Kim YM, Casey CP, Stratton KG, Webb-Robertson BM, Gritsenko MA, Monroe ME, Weitz KK, Shukla AK, Tian M, Neumann G, Reed JL, van Bakel H, Metz TO, Smith RD, Waters KM, N'jai A, Sahr F, Kawaoka Y.

Cell Host Microbe. 2017 Dec 13;22(6):817-829.e8. doi: 10.1016/j.chom.2017.10.011. Epub 2017 Nov 16.

PMID:
29154144
38.

Reactivity and sensitivity of commercially available influenza rapid diagnostic tests in Japan.

Sakai-Tagawa Y, Yamayoshi S, Kawakami C, Le MQ, Uchida Y, Saito T, Nidom CA, Humaira I, Toohey-Kurth K, Arafa AS, Liu MT, Shu Y, Kawaoka Y.

Sci Rep. 2017 Nov 3;7(1):14483. doi: 10.1038/s41598-017-14536-0.

39.

NS1 is the fluid for "flu-transmission".

Watanabe T, Imai M, Kawaoka Y.

Proc Natl Acad Sci U S A. 2017 Oct 17;114(42):11012-11014. doi: 10.1073/pnas.1715239114. Epub 2017 Oct 10. No abstract available.

40.

A Highly Pathogenic Avian H7N9 Influenza Virus Isolated from A Human Is Lethal in Some Ferrets Infected via Respiratory Droplets.

Imai M, Watanabe T, Kiso M, Nakajima N, Yamayoshi S, Iwatsuki-Horimoto K, Hatta M, Yamada S, Ito M, Sakai-Tagawa Y, Shirakura M, Takashita E, Fujisaki S, McBride R, Thompson AJ, Takahashi K, Maemura T, Mitake H, Chiba S, Zhong G, Fan S, Oishi K, Yasuhara A, Takada K, Nakao T, Fukuyama S, Yamashita M, Lopes TJS, Neumann G, Odagiri T, Watanabe S, Shu Y, Paulson JC, Hasegawa H, Kawaoka Y.

Cell Host Microbe. 2017 Nov 8;22(5):615-626.e8. doi: 10.1016/j.chom.2017.09.008. Epub 2017 Oct 19.

PMID:
29056430
41.

Emergence of Oseltamivir-Resistant H7N9 Influenza Viruses in Immunosuppressed Cynomolgus Macaques.

Kiso M, Iwatsuki-Horimoto K, Yamayoshi S, Uraki R, Ito M, Nakajima N, Yamada S, Imai M, Kawakami E, Tomita Y, Fukuyama S, Itoh Y, Ogasawara K, Lopes TJS, Watanabe T, Moncla LH, Hasegawa H, Friedrich TC, Neumann G, Kawaoka Y.

J Infect Dis. 2017 Sep 1;216(5):582-593. doi: 10.1093/infdis/jix296.

PMID:
28931216
42.

Calculated risk: a new single-nucleotide polymorphism linked to severe influenza disease.

Eisfeld AJ, Kawaoka Y.

Nat Med. 2017 Aug 4;23(8):911-912. doi: 10.1038/nm.4383. No abstract available.

PMID:
28777788
43.

M2SR, a novel live influenza vaccine, protects mice and ferrets against highly pathogenic avian influenza.

Hatta Y, Boltz D, Sarawar S, Kawaoka Y, Neumann G, Bilsel P.

Vaccine. 2017 Jul 24;35(33):4177-4183. doi: 10.1016/j.vaccine.2017.06.039. Epub 2017 Jun 28.

44.

Inside the Cell: Assembly of Filoviruses.

Kolesnikova L, Nanbo A, Becker S, Kawaoka Y.

Curr Top Microbiol Immunol. 2017;411:353-380. doi: 10.1007/82_2017_15.

PMID:
28601948
45.

Ebolavirus's Foibles.

Yamayoshi S, Kawaoka Y.

Cell. 2017 May 18;169(5):773-775. doi: 10.1016/j.cell.2017.05.008.

46.

A Broadly Reactive Human Anti-hemagglutinin Stem Monoclonal Antibody That Inhibits Influenza A Virus Particle Release.

Yamayoshi S, Uraki R, Ito M, Kiso M, Nakatsu S, Yasuhara A, Oishi K, Sasaki T, Ikuta K, Kawaoka Y.

EBioMedicine. 2017 Mar;17:182-191. doi: 10.1016/j.ebiom.2017.03.007. Epub 2017 Mar 6.

47.

Evaluation of seasonal influenza vaccines for H1N1pdm09 and type B viruses based on a replication-incompetent PB2-KO virus.

Ui H, Yamayoshi S, Uraki R, Kiso M, Oishi K, Murakami S, Mimori S, Kawaoka Y.

Vaccine. 2017 Apr 4;35(15):1892-1897. doi: 10.1016/j.vaccine.2017.02.041. Epub 2017 Mar 9.

PMID:
28285982
48.

Potential risk of repeated nasal vaccination that induces allergic reaction with mucosal IgE and airway eosinophilic infiltration in cynomolgus macaques infected with H5N1 highly pathogenic avian influenza virus.

Nakayama M, Itoh Y, Shichinohe S, Nakabayashi R, Ishigaki H, Sakoda Y, Le QM, Kawaoka Y, Kida H, Ogasawara K.

Vaccine. 2017 Feb 15;35(7):1008-1017. doi: 10.1016/j.vaccine.2017.01.008. Epub 2017 Jan 18.

PMID:
28109707
49.

Glycosylation of the Hemagglutinin Protein of H5N1 Influenza Virus Increases Its Virulence in Mice by Exacerbating the Host Immune Response.

Zhao D, Liang L, Wang S, Nakao T, Li Y, Liu L, Guan Y, Fukuyama S, Bu Z, Kawaoka Y, Chen H.

J Virol. 2017 Mar 13;91(7). pii: e02215-16. doi: 10.1128/JVI.02215-16. Print 2017 Apr 1.

50.

MPLEx: a method for simultaneous pathogen inactivation and extraction of samples for multi-omics profiling.

Burnum-Johnson KE, Kyle JE, Eisfeld AJ, Casey CP, Stratton KG, Gonzalez JF, Habyarimana F, Negretti NM, Sims AC, Chauhan S, Thackray LB, Halfmann PJ, Walters KB, Kim YM, Zink EM, Nicora CD, Weitz KK, Webb-Robertson BM, Nakayasu ES, Ahmer B, Konkel ME, Motin V, Baric RS, Diamond MS, Kawaoka Y, Waters KM, Smith RD, Metz TO.

Analyst. 2017 Jan 26;142(3):442-448. doi: 10.1039/c6an02486f.

Supplemental Content

Loading ...
Support Center